Avidity Partners Management LP Zentalis Pharmaceuticals, Inc. Transaction History

Avidity Partners Management LP

$1.63 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$19.63 - $28.29 $4.59 Million - $6.62 Million	-234,000 Reduced 10.03%	2,100,000 $42.1 Million
Q2 2023 Aug 14, 2023	SELL	$17.41 - $30.05 $10.4 Million - $17.9 Million	-595,300 Reduced 20.32%	2,334,000 $65.8 Million
Q1 2023 May 15, 2023	SELL	$16.14 - $24.94 $35.8 Million - $55.4 Million	-2,220,700 Reduced 43.12%	2,929,300 $50.4 Million
Q4 2022 Feb 14, 2023	BUY	$18.07 - $25.6 $16.7 Million - $23.7 Million	926,900 Added 21.95%	5,150,000 $104 Million
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $12.9 Million - $20.2 Million	637,219 Added 17.77%	4,223,100 $91.5 Million
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $7.32 Million - $21.4 Million	408,882 Added 12.87%	3,585,881 $101 Million
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $19.2 Million - $37.4 Million	461,999 Added 17.02%	3,176,999 $147 Million
Q4 2021 Feb 14, 2022	BUY	$66.92 - $84.79 $14.8 Million - $18.8 Million	221,200 Added 8.87%	2,715,000 $228 Million
Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $15.6 Million - $24.5 Million	333,800 Added 15.45%	2,493,800 $166 Million
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $33.5 Million - $55.8 Million	896,700 Added 70.98%	2,160,000 $115 Million
Q1 2021 May 17, 2021	BUY	$35.69 - $52.72 $4.58 Million - $6.76 Million	128,300 Added 11.3%	1,263,300 $54.8 Million
Q4 2020 Feb 16, 2021	BUY	$31.71 - $57.97 $7.32 Million - $13.4 Million	230,881 Added 25.54%	1,135,000 $59 Million
Q3 2020 Nov 16, 2020	BUY	$27.03 - $47.97 $6.21 Million - $11 Million	229,632 Added 34.05%	904,119 $29.6 Million
Q2 2020 Aug 14, 2020	BUY	$23.2 - $54.8 $15.6 Million - $37 Million	674,487 New	674,487 $32.4 Million

Others Institutions Holding ZNTL

# of Institutions

142

Shares Held

67.9M

Call Options Held

48.5K

Put Options Held

89.6K

Matrix Capital Management Company, LP Waltham, MA

14M
Shares

$40.8 Million
2.45% of portfolio
Eventide Asset Management, LLC Boston, MA

8.55M
Shares

$25 Million
0.55% of portfolio
Black Rock Inc. New York, NY

4.82M
Shares

$14.1 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.61M
Shares

$13.5 Million
0.0% of portfolio
Decheng Capital LLC Menlo Park, CA

3.11M
Shares

$9.08 Million
2.71% of portfolio

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $166M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.

Account